SCHEMBL1980896

SCHEMBL1980896

O=C(O)C(F)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.51
SLC1A2 P43004 1/20 0.51
SLC1A1 P43005 1/20 0.51
CA1 P00915 4/20 0.50
CA2 P00918 4/20 0.50
MMP2 P08253 3/20 0.50
MMP9 P14780 3/20 0.50
MMP1 P03956 2/20 0.50
MMP13 P45452 2/20 0.50
MMP8 P22894 1/20 0.50
MMP3 P08254 1/20 0.49
MMP7 P09237 1/20 0.49
LMNA P02545 1/20 0.45
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
F2 P00734 2/20 0.42
PRSS1 P07477 2/20 0.42
PRSS2 P07478 2/20 0.42
PRSS3 P35030 2/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27364450 0.83 MMP2 (0.46) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL16232170 0.80 MMP2 (0.50) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL9732244 0.78 CA1 (0.46) CA1CA2MMP2MMP9MMP1
SCHEMBL8119090 0.72 PKM (0.53) ALDH1A1
SCHEMBL27874923 0.72 F2 (0.47) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL7468791 0.72 ADAMTS4 (0.69) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL7468779 0.72 ADAMTS4 (0.69) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL6806364 0.72 ADAMTS4 (0.69) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL13822716 0.72 ALDH1A1 (0.43) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL11764655 0.71 CA1 (0.45) CA1CA2MMP2MMP9MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889696-B2 Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof Temple University—Of the Commonwealth System of Higher Education (US) 2014-11-18 US disclosed
US-20120269831-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-10-25 US disclosed
EP-2512250-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF Temple University - Of The Commonwealth System of Higher Education (US) 2012-10-24 EP disclosed
WO-2011075616-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269831-A1 SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AND THERAPEUTIC USES THEREOF MKI67, CCNA1, FOLR1 SLC1A3 2891/4885SLC1A2 2560/4885SLC1A1 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.